Rigel Pharmaceuticals Cash Flow To Debt Ratio Over Time
| RIGL Stock | USD 27.61 0.27 0.97% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Rigel Pharmaceuticals Performance and Rigel Pharmaceuticals Correlation. Rigel |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Rigel Pharmaceuticals. If investors know Rigel will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Rigel Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.48) | Earnings Share 0.27 | Revenue Per Share 8.979 | Quarterly Revenue Growth 0.966 | Return On Assets 0.0461 |
The market value of Rigel Pharmaceuticals is measured differently than its book value, which is the value of Rigel that is recorded on the company's balance sheet. Investors also form their own opinion of Rigel Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Rigel Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Rigel Pharmaceuticals' market value can be influenced by many factors that don't directly affect Rigel Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Rigel Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Rigel Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Rigel Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Cash Flow To Debt Ratio Analysis
Compare Rigel Pharmaceuticals and related stocks such as Fortress Biotech, Reviva Pharmaceuticals, and CTi Biopharma Corp Cash Flow To Debt Ratio Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| FBIO | (14.6027) | (14.6027) | (1.5905) | (2.177) | (1.166) | (0.8793) | (1.6237) | (1.3669) | (1.2433) | (1.0386) | (1.3007) | (2.2461) | (1.7363) | (1.8916) | (1.99) |
| RVPH | (0.058) | (0.058) | (0.058) | (0.058) | (0.058) | (0.058) | (0.058) | (0.058) | (0.058) | (0.058) | (0.058) | (0.058) | (0.058) | (0.0522) | (0.0548) |
| PIRS | (0.6476) | (0.6476) | (0.6476) | (0.6476) | (3.9868) | (3.9868) | (3.9868) | (3.9868) | (3.9868) | (3.9868) | (3.9868) | (3.9868) | (3.9868) | (4.58) | (4.81) |
| CDTX | (0.7067) | (0.7067) | (0.7067) | (0.7067) | (4.0608) | (4.0608) | (4.0608) | (5.0551) | (5.7116) | (2.646) | (6.8338) | (6.7483) | (17.2554) | (19.84) | (18.85) |
| XFOR | (1.5037) | (1.5037) | (1.5037) | (1.5037) | (1.5037) | (1.5037) | (1.4178) | (2.2778) | (4.2692) | (2.2889) | (1.7318) | (2.0253) | (2.2145) | (1.7337) | (1.82) |
| MREO | (8.7636) | (8.7636) | (8.7636) | (8.7636) | (8.7636) | (8.7636) | (8.7636) | (1.5491) | (1.0769) | (2.0705) | (1.7557) | (3.5216) | (3.5216) | (4.8093) | (5.05) |
| INZY | (65.8728) | (65.8728) | (65.8728) | (65.8728) | (65.8728) | (65.8728) | (65.8728) | (65.8728) | (65.8728) | (65.8728) | (65.8728) | (65.8728) | (11.6571) | (1.5472) | (1.62) |
| TERN | (2.3144) | (2.3144) | (2.3144) | (2.3144) | (2.3144) | (2.3144) | (2.3144) | (2.3144) | (2.3144) | (2.3144) | (2.3144) | (74.295) | (74.295) | (112) | (117) |
| LPTX | (6.2338) | (6.2338) | (6.2338) | (6.2338) | (6.2338) | (6.2338) | (0.8369) | (56.7553) | (56.7553) | (56.7553) | (63.6201) | (81.3819) | (118) | (167) | (159) |
| ZURA | (0.0833) | (0.0833) | (0.0833) | (0.0833) | (0.0833) | (0.0833) | (0.0833) | (0.0833) | (0.0833) | (0.0833) | (0.0833) | (0.0833) | (0.0833) | (0.075) | (0.0787) |
| ENVB | (34.6628) | (3.1062) | (3.1062) | (10.816) | (0.5888) | (0.5888) | (0.5375) | (0.3815) | (0.4927) | (0.5026) | (107) | (107) | (269) | (309) | (294) |
| IMMX | (0.1927) | (0.1927) | (0.1927) | (0.1927) | (0.1927) | (0.1927) | (0.1927) | (0.1927) | (0.1927) | (0.1927) | (0.0987) | (31.7861) | (31.7861) | (36.55) | (34.73) |
| ELEV | (2.9041) | (2.9041) | (2.9041) | (2.9041) | (2.9041) | (2.9041) | (2.9041) | (2.9041) | (2.9041) | (2.9041) | (2.9041) | (2.9041) | (2.9041) | (1.8642) | (1.96) |
| DAWN | (238) | (238) | (238) | (238) | (238) | (238) | (238) | (238) | (238) | (238) | (238) | (238) | (271) | (360) | (378) |
| ABOS | (335) | (335) | (335) | (335) | (335) | (335) | (335) | (335) | (335) | (335) | (335) | (335) | (335) | (1.5269) | (1.6) |
Rigel Pharmaceuticals and related stocks such as Fortress Biotech, Reviva Pharmaceuticals, and CTi Biopharma Corp Cash Flow To Debt Ratio description
My Equities
My Current Equities and Potential Positions
| Rigel Pharmaceuticals | RIGL |
| Classification | Cancer Fighters |
| Location | California; U.S.A |
| Exchange | NASDAQ Exchange |
USD 27.61
Check out Rigel Pharmaceuticals Performance and Rigel Pharmaceuticals Correlation. For more information on how to buy Rigel Stock please use our How to buy in Rigel Stock guide.You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.
Rigel Pharmaceuticals technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.